[CLINICAL EFFICACY OF 69 PATIENTS WITH JAPANESE CEDAR POLLINOSIS TREATED BY SUBLINGUAL IMMUNOTHERAPY WITH CEDARCURE ® IN THE FIRST FOLLOW-UP YEAR].

Background: Cedarcure ^® for sublingual immunotherapy of cedar pollinosis was purchased in 2018. We studied clinical efficacy of Cedarcure ^® in the first year.
Methods: We compared 69 patients treated with Cedarcure ^® (age, 18.0±13.5 years; male-to-female ratio, 40;29) and a control group of 97 patients treated with Cedartolen ^® (age, 29.8±16.2 years; male-to-female ratio, 44;53) during the peak season of large amount of pollen dispersal (10933 grains/cm2/season) in 2019. The clinical efficacy was evaluated by assessing symptom scores by Japanese rhino-conjunctivitis quality of life questionnaire and visual analog scale (VAS).
Results: All the assessments except nasal congestion were slightly better in Cedarcure ^® group, but they were not significant. There was no difference of concomitant medication in both groups. Because insurance coverage of Cedartolen ^® is for patients over 12 years old in Japan, the efficacy in Cedarcure ^® group enhanced better in all assessments if comparing the patients of over 12 years old. Percentage of adverse events was even in both over and under 12 years old.
Conclusion: Cedarcure ^® was treated in safe, and reduced symptoms as well as Cedartolen ^® .